The size of the Cell-Based Assay Market in Europe was worth USD 4.95 billion in 2024 and is estimated to be growing at a CAGR of 10.84% to reach USD 8.28 billion by 2029. Europe is the second-largest cell-based assay market.
The rising incidence of chronic cases, growing demand for cell-based assays are majorly driving growth for the European cell-based assay market. Additionally, increasing R&D activities towards the innovations to battle deadly diseases such as cancer, cardiovascular diseases, and others are estimated to add fuel to the market's growth rate in Europe. Wide usage of these cell-based assays in applications such as diagnostics and pathology, rise in funds by government and other private sectors for R&D are predicted to favor the European market during the forecast period. Furthermore, growing awareness related to the applications of cell-based assays is a positive sign.
Lack of experienced professionals is to hinder the cell-based assay market growth during the analysis period. Also, the high cost of the instruments and strict regulatory recommendations may hamper the growth. Moreover, boundaries on reagent use may also obstruct the market.
This research report on the Europe Cell-Based Assay Market has been segmented and sub-segmented into the following categories:
By Type Of Product:
By Technology:
By Application:
By End Users:
By Country:
Regionally, Spain and Italy are the fastest emerging markets in the European region for the cell-based assay market. An increase in the adoption of cell-based assays platforms and enormous biotechnology and pharmaceutical companies in the area augment market growth. Advance technologies in activities like improved systems, innovative and disposable columns, better-performing resins, and alternative accessories square measures help the cell-based assays market grow considerably. Growing expenditure by the government sector to lessen the death rates from cancer is responsible for market growth.
Noteworthy companies leading the European Cell-Based Assay Market profiled in this report are Thermo Fisher Scientific Inc., Becton & Dickinson and Company, Merck & Co. Inc., Cell Signalling Technology Inc., PerkinElmer Inc., Danaher Corporation, General Electric Company, Cisbio Bioassays, DiscoveRx, Ametek Inc., Bio-Rad Laboratories, Roche Diagnostics, GE Healthcare, and Promega Corporation.
Related Reports
Access the study in MULTIPLE FORMATS
Purchase options starting from $ 1400
Didn’t find what you’re looking for?
TALK TO OUR ANALYST TEAM
Need something within your budget?
NO WORRIES! WE GOT YOU COVERED!
Call us on: +1 888 702 9696 (U.S Toll Free)
Write to us: [email protected]
Reports By Region